Pharnext: Funding, Investors & Team (Sep 2026)
Pharnext is an advanced clinical-stage biopharmaceutical company founded in April 2007 by renowned scientists and entrepreneurs including Professor Daniel Cohen and collaborators, pioneers in modern genomics. The company develops new therapeutics for neurodegenerative diseases - orphan and common – where there are currently no cures and existing therapies available. Pharnext is the pioneer of a new paradigm for the discovery of medicinal drugs: PLEOTHERAPY™. The R&D approach protected by Pharnext systemizes new uses of approved drugs. It is based on network pharmacology utilizing complex and extensive genomic data to identify the thousands of molecules possibly involved in a disease. From this disease molecular network, Pharnext deduces synergistic combinations of drugs already approved but for unrelated indications. These novel therapeutics called PLEODRUG™ are then developed at new optimal doses and under new formulations. They offer several key advantages: efficacy, safety, and intellectual property including several composition of matter patents already granted. The proof of concept of the PLEOTHERAPY approach was obtained with PLEODRUG PXT3003 in Charcot-Marie-Tooth disease type 1A (CMT1A) through positive and consistent Phase 2 and Phase 3 results. PLEODRUG PXT864 generated encouraging Phase 2 data in Alzheimer’s disease. They also plan to develop the same agent in other orphan and common neurodegenerative diseases such as Parkinson’s disease and amyotrophic lateral sclerosis (ALS).
Pharnext has raised $298M across 2 funding rounds on record, the most recent an undisclosed round of $199M announced in Sep 2022.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Pharnext Company Profile and Key Stats
Latest funding round on record: Sep 2022.
Pharnext Funding Rounds
Pharnext raised $98.7M in an undisclosed round announced in Jun 2021.
1.3 years later, an undisclosed round of $199M was announced in Sep 2022.
Pharnext Founders and Leadership Team
No contact details are on record for this team yet.
Pharnext Funding Compared to Other Biotechnology Startups
Pharnext's latest round of $199M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Pharnext in Biotechnology and Issy-les-moulineaux
Companies Similar to Pharnext
Brenus Pharma is a platform that uses allogeneic techniques to create immune therapy with the goal of…
TISSIUM is a privately owned medical device company based in Paris, France that is dedicated to the rapid…
NicOx is a biopharmaceutical company that focuses on creating and selling nitric oxide-donating drugs for…
Advicenne is a specialty pharmaceutical company dedicated to improving the lives of patients who suffer from…
One Biosciences was founded in Paris, Ile-de-France, France by Magali Richard, David Schilansky, and Céline…
Inventiva Pharma is a biopharmaceutical company in the clinical stage that focuses on creating oral small…
NETRIS Pharma develops therapeutic molecules for treating cancer by targeting dependence receptors for the…
AbIONYX Pharma is a biotechnology company that is focused on providing innovative therapies for indications…
Founded in 2003, Nanobiotix is at the forefront of nanomedicine and is committed to revolutionizing patient…
Theraclion specializes in high-tech medical equipment using high-intensity focused ultrasound (HIFU). They…
Abivax, a clinical stage biotechnology company, is mobilizing the body’s natural immune machinery to treat…
AB Science was established in 2001 by a group of individuals in the medical and business fields who are…
Pharnext Funding FAQs
What does Pharnext do?
Pharnext is an advanced clinical-stage biopharmaceutical company founded in April 2007 by renowned scientists and entrepreneurs including Professor Daniel Cohen and collaborators, pioneers in modern genomics. The company develops new therapeutics for neurodegenerative diseases - orphan and common – where there are currently no cures and existing therapies available. Pharnext is the pioneer of a new paradigm for the discovery of medicinal drugs: PLEOTHERAPY™. The R&D approach protected by Pharnext systemizes new uses of approved drugs. It is based on network pharmacology utilizing complex and extensive genomic data to identify the thousands of molecules possibly involved in a disease. From this disease molecular network, Pharnext deduces synergistic combinations of drugs already approved but for unrelated indications. These novel therapeutics called PLEODRUG™ are then developed at new optimal doses and under new formulations. They offer several key advantages: efficacy, safety, and intellectual property including several composition of matter patents already granted. The proof of concept of the PLEOTHERAPY approach was obtained with PLEODRUG PXT3003 in Charcot-Marie-Tooth disease type 1A (CMT1A) through positive and consistent Phase 2 and Phase 3 results. PLEODRUG PXT864 generated encouraging Phase 2 data in Alzheimer’s disease. They also plan to develop the same agent in other orphan and common neurodegenerative diseases such as Parkinson’s disease and amyotrophic lateral sclerosis (ALS).
How much funding has Pharnext raised?
Pharnext has raised $298M across 2 rounds on record. The most recent is an undisclosed round of $199M announced in Sep 2022.
When did Pharnext last raise funding?
Pharnext's most recent funding round on record is an undisclosed round of $199M, announced in Sep 2022.
Who is the CEO of Pharnext?
Daniel Cohen is listed as CEO at Pharnext.
Where is Pharnext headquartered?
Pharnext is based in Issy-les-moulineaux, Ile-De-France, France.
How many employees does Pharnext have?
Pharnext is in the 11-50 employee band.
How does Pharnext's funding compare to other Biotechnology startups?
Pharnext's latest round of $199M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,183 tracked companies over the last two years.
About FundedIQ's Pharnext Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Pharnext is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.